Sign in
Taking people in SpainPhase 1/2

Tests IDP-121 in adults with relapsed or hard-to-treat blood cancers

Tests the new drug IDP-121 in adults with lymphoma, leukemia or myeloma.

Key facts

Who runs it
Idp Discovery Pharma S.L.
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Murcia, Salamanca, Santander, Sevilla, Valencia, and Zaragoza, SpainSee the 12 sites
Registry title
Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)
Status
Recruiting
Phase
Phase 1/2
People taking part
62 people, planned
Started
6 Jun 2023
Planned end
31 Dec 2025
Type of study
Interventional
Record updated
26 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic lymphocytic leukemia, B-cell lymphoma or multiple myeloma who cannot receive the available treatments.

Age
18 years or older
Sex
Women and men
Disease stage
Chronic lymphocytic leukemia (CLL), B-cell lymphomas or multiple myeloma (MM) in people who cannot receive the available treatments. ECOG performance status of 2 or lower. Life expectancy of 3 months or more.
Earlier treatment
No other anti-tumor therapy within 14 days before Day 1 of Cycle 1. No allogeneic transplant in the last 3 months. No active graft-versus-host disease treated with immunosuppressive treatment.
Biomarker or test result
Blood counts, liver tests and kidney function must be in the ranges set by the trial. Left ventricular ejection fraction above 50% or above the institution's lower limit of normal, whichever is lower.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Clinically significant or active infection
  • Another cancer in the last five years (with a few skin and in situ exceptions)
  • Heart failure, angina or heart attack within 12 months, or uncontrolled high blood pressure or heart rhythm problems
  • Significant vascular disease, or significant non-cancer liver disease

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age ≥18 years
  • Performance status (ECOG) ≤ 2
  • Life expectancy ≥3 months
  • Patient is, in the investigator’s opinion, willing and able to comply with the protocol requirements
  • Patient has given voluntary written informed consent before performance of any studyrelated procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care
  • Patients diagnosed with chronic lymphocytic leukemia (CLL), B-cell lymphomas, and multiple myeloma (MM) who are ineligible to receive the available treatments
  • Adequate hematological or biochemical parameters as specified below a. Hemoglobin > 8.0 g/dl (without transfusion support within 7 days) b. Platelets count > 75 x109/L (without transfusional support within 7 days). In patients with bone marrow infiltration, the platelets count may be ≥50 x109/L. c. Absolute neutrophil count (ANC) > 0.75 x109/L (without G-CSF support within 7 days) d. Aspartate transaminase (AST): <2.5 x the upper limit range (in patients with no liver metastases or <5 x ULN in patients with liver metastases) e. Alanine transaminase (ALT): < 2.5 x the upper limit range (in patients with no liver metastases or <5 x ULN in patients with liver metastases) f. Total bilirubin: < 2 x the upper limit range. g. Calculated or measured creatinine clearance: >30 mL/min (calculated from the Cockcroft-Gault formula)
  • Left ventricular ejection fraction > 50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower, determined by echocardiogram

Who cannot take part

  • Persistent clinically significant non-hematological toxicity related to previous treatments. The presence of alopecia and NCI-CTC grade <2 symptomatic peripheral neuropathy is allowed
  • The patient is known to be human immunodeficiency virus (HIV) positive, unless the patient is on antiviral therapy with HIV RNA levels <50 copies/mL; Hepatitis B surface antigen-positive or active hepatitis C infection, unless treated with undetectable hepatitis B DNA or hepatitis C RNA levels; or active CMV infection (IgM positive)
  • Concomitant anti-tumor therapy within 14 days prior to Day 1 of Cycle 1
  • Prior allogeneic transplantation in the last 3 months or currently active GVHD with immunosuppressive treatment
  • If a COVID-19 vaccine is administered, it should be done >72 hours prior to study treatment initiation or after the completion of the dose-limiting toxicity (DLT) period (if patient is participating in the dose-escalation phase”)
  • Other relevant diseases or adverse clinical conditions: - Congestive heart failure or angina pectoris, myocardial infarction within 12 months before inclusion in the study. - Uncontrolled arterial hypertension or cardiac arrhythmias (i.e., requiring a change in medication within the last 3 months or hospital admission within the past 6 months). - History of significant neurological or psychiatric disorders
  • History of any other neoplastic disease in the last five years (except basal cell carcinoma, skin epithelioma or carcinoma in situ of any site)
  • History of clinically significant hypotension
  • History of clinically significant allergic or hyper-sensitivity reactions
  • History or known clinically significant vascular disease or known high risk of vascular disease (as assessed by the treating physician) including (but not limited to): - Thromboembolism - Peripheral arterial disease - Vasculitis
  • Clinically significant or active infection
  • Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis)
  • Limitation of the patient’s ability to comply with the treatment or follow-up protocol
  • Pregnant or lactating women; men and women of reproductive potential who are not using effective contraceptive methods (combined hormonal contraception associated with inhibition of ovulation; progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinenence)

Where in Spain

  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
  • Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpainTaking people
  • Hospital Universitario 12 de OctubreMadrid, SpainTaking people
  • Hospital Universitario La PazMadrid, SpainTaking people
  • Hospital Universitario Puerta de Hierro de MajadahondaMajadahonda, SpainTaking people
  • University Clinical Hospital Virgen De La ArrixacaMurcia, SpainTaking people
  • Hospital Universitario De SalamancaSalamanca, SpainTaking people
  • Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
  • University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
  • Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
  • Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
  • Hospital Universitario Miguel ServetZaragoza, SpainTaking people

About the trial

What the trial wants to find out

Dose-Escalation Phase (Phase 1): To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), B-cell lymphoma, and chronic lymphocytic leukemia (CLL).

Read full original descriptionShow less

Expansion Phase (Phase 2): To evaluate the overall response rate (ORR) in patients with MM, B-cell lymphoma or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)
Plain-language title
Tests IDP-121 in adults with relapsed or hard-to-treat blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
26 June 2026